$ACST Thinking out loud about CV outcome trial necessity: if CaPre is successful with trifecta effect on LDL and HDL management, then could they rely on the argument that it is already proven that an improved cholesterol profile reduces the chances of a CV event? AHA makes it very clear that management of cholesterol levels can reduce risk of CV event... Also they would then probably be able to prove that CaPre improves omega-3 index substantially...which is also proven to have a direct correlation with heart diseases.... Obviously it would not replace a full outcome trial, but I think it could get them started quite well. Any thoughts?
  • 2
  • 2